Press Releases

Additional Phase 2 trial of the OCA-bezafibrate combination remains ongoing in Europe MORRISTOWN, N.J. , May 11, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat

Worldwide Ocaliva ® net sales of $88.6 million , representing 8% growth over the prior year quarter Nearing completion of new REGENERATE data analyses; planning for potential pre-submission meeting with FDA in June Continue to expect topline results from Phase 3 REVERSE study in compensated

Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® for PBC outside the U.S. , as well as the transition to Advanz of the international commercial and medical infrastructure of Intercept Additionally, Intercept will receive royalties on any future ex- U.S.

MORRISTOWN, N.J. , May 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2022 financial

Worldwide Ocaliva® net sales of $92.4 million and $363.5 million for the fourth quarter and full year 2021, representing 11% and 16% growth over the prior year Company provides 2022 Ocaliva net sales guidance of $375 million to $405 million and non-GAAP adjusted operating expense guidance of $360

NEW YORK , Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2021

Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the year NEW YORK , Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat

NEW YORK , Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has formally notified the European

Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK -PBC databases Results will be featured in a late-breaking podium presentation at The Liver Meeting ® NEW YORK , Nov.

NEW YORK , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief